60 related articles for article (PubMed ID: 22690572)
1. [Treatment of mild exacerbations of chronic obstructive pulmonary disease].
Kliachkina IL; Dmitriev IuK
Klin Med (Mosk); 2012; 90(3):69-73. PubMed ID: 22690572
[TBL] [Abstract][Full Text] [Related]
2. Efficacy, safety and tolerability of salbutamol + guaiphenesin + bromhexine (Ascoril) expectorant versus expectorants containing salbutamol and either guaiphenesin or bromhexine in productive cough: a randomised controlled comparative study.
Prabhu Shankar S; Chandrashekharan S; Bolmall CS; Baliga V
J Indian Med Assoc; 2010 May; 108(5):313-4, 316-8, 320. PubMed ID: 21121410
[TBL] [Abstract][Full Text] [Related]
3. Plant-based formulation in the management of chronic obstructive pulmonary disease: a randomized double-blind study.
Murali PM; Rajasekaran S; Paramesh P; Krishnarajasekar OR; Vasudevan S; Nalini K; Lakshmisubramanian S; Deivanayagam CN
Respir Med; 2006 Jan; 100(1):39-45. PubMed ID: 15905081
[TBL] [Abstract][Full Text] [Related]
4. [Effect of mucolytic therapy on the production of reactive oxygen species in the blood of patients with an exacerbation of chronic obstructive pulmonary disease].
Farkhutdinov UR; Farkhutdinov RR; Petriakov VV; Farkhutdinov ShU; Mirkhaĭdarov AM
Ter Arkh; 2010; 82(3):29-32. PubMed ID: 20564918
[TBL] [Abstract][Full Text] [Related]
5. Exacerbations of chronic obstructive pulmonary disease.
Wedzicha JA; Donaldson GC
Respir Care; 2003 Dec; 48(12):1204-13; discussion 1213-5. PubMed ID: 14651761
[TBL] [Abstract][Full Text] [Related]
6. [The combined drug ascoril in the treatment of patients with chronic obstructive pulmonary disease concurrent with coronary heart disease].
Grigor'eva NIu; Kuznetsov AN; Koroleva TV; Koroleva ME
Ter Arkh; 2013; 85(8):91-4. PubMed ID: 24137971
[TBL] [Abstract][Full Text] [Related]
7. [Chronic obstructive pulmonary disease exacerbation. Do we use all possibilities of outpatient therapy?].
Leshchenko IV
Ter Arkh; 2013; 85(10):83-7. PubMed ID: 24437224
[TBL] [Abstract][Full Text] [Related]
8. Tiotropium versus salmeterol for the prevention of exacerbations of COPD.
Vogelmeier C; Hederer B; Glaab T; Schmidt H; Rutten-van Mölken MP; Beeh KM; Rabe KF; Fabbri LM;
N Engl J Med; 2011 Mar; 364(12):1093-1103. PubMed ID: 21428765
[TBL] [Abstract][Full Text] [Related]
9. [Combination of inhaled salmeterol/fluticasone and tiotropium in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial].
Fang LZ; Liang X; Zhang JQ; Liu L; Fu WP; Zhao ZH; Dai LM
Zhonghua Jie He He Hu Xi Za Zhi; 2008 Nov; 31(11):811-4. PubMed ID: 19080533
[TBL] [Abstract][Full Text] [Related]
10. Comparison of levalbuterol and racemic albuterol in hospitalized patients with acute asthma or COPD: a 2-week, multicenter, randomized, open-label study.
Donohue JF; Hanania NA; Ciubotaru RL; Noe L; Pasta DJ; Schaefer K; Claus R; Andrews WT; Roach J
Clin Ther; 2008; 30 Spec No():989-1002. PubMed ID: 18640474
[TBL] [Abstract][Full Text] [Related]
11. Risk of hospitalizations/emergency department visits and treatment costs associated with initial maintenance therapy using fluticasone propionate 500 microg/salmeterol 50 microg compared with ipratropium for chronic obstructive pulmonary disease in older adults.
Blanchette CM; Akazawa M; Dalal A; Simoni-Wastila L
Am J Geriatr Pharmacother; 2008 Aug; 6(3):138-46. PubMed ID: 18775388
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.
Kerwin EM; Gotfried MH; Lawrence D; Lassen C; Kramer B
Clin Ther; 2011 Dec; 33(12):1974-84. PubMed ID: 22177371
[TBL] [Abstract][Full Text] [Related]
13. Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations.
Ferguson GT; Anzueto A; Fei R; Emmett A; Knobil K; Kalberg C
Respir Med; 2008 Aug; 102(8):1099-108. PubMed ID: 18614347
[TBL] [Abstract][Full Text] [Related]
14. [Observation of the therapeutic effect on COPD of cold phlegm blocking the lung type at stable stage treated with acupoint sticking therapy in different season].
Yang SQ; Zhang W; Li JX; Lou BD; Li XP; Li W; Huang XH; Liu XP; Yang LB; Shi WY; Cao Y
Zhongguo Zhen Jiu; 2012 Feb; 32(2):117-22. PubMed ID: 22493913
[TBL] [Abstract][Full Text] [Related]
15. Value of adding a polyvalent mechanical bacterial lysate to therapy of COPD patients under regular treatment with salmeterol/fluticasone.
Cazzola M; Noschese P; Di Perna F
Ther Adv Respir Dis; 2009 Apr; 3(2):59-63. PubMed ID: 19443519
[TBL] [Abstract][Full Text] [Related]
16. Erdosteine enhances airway response to salbutamol in patients with mild-to-moderate COPD.
Dal Negro R; Visconti M; Trevisan F; Bertacco S; Micheletto C; Tognella S
Ther Adv Respir Dis; 2008 Oct; 2(5):271-7. PubMed ID: 19124377
[TBL] [Abstract][Full Text] [Related]
17. [Relationship between SGRQ score and pulmonary function and its influencing factors in patients with chronic obstructive pulmonary disease].
Liu R; DU YP; He B
Zhonghua Yi Xue Za Zhi; 2011 Jun; 91(22):1533-7. PubMed ID: 21914365
[TBL] [Abstract][Full Text] [Related]
18. [The effect of inhaled ambroxol treatment on clinical symptoms and chosen parameters of ventilation in patients with exacerbation of chronic obstructive pulmonary disease patients].
Jahnz-Rózyk K; Kucharczyk A; Chciałowski A; Płusa T
Pol Merkur Lekarski; 2001 Sep; 11(63):239-43. PubMed ID: 11761819
[TBL] [Abstract][Full Text] [Related]
19. [Influence of Broncho-Vaxom treatment on serum concentration of metalloproteinase-9 in patients with chronic obstructive pulmonary disease].
Targowski T; Jahnz-Rózyk K; Płusa T; Niedziałkowski P; Rozyńska R
Pol Merkur Lekarski; 2005 Nov; 19(113):630-3. PubMed ID: 16498799
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of Ascoril in the management of cough--National Study Group report.
Ainapure SS; Desai A; Korde K
J Indian Med Assoc; 2001 Feb; 99(2):111, 114. PubMed ID: 11482804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
